| Ytd | 79.54% | |
| 1y | 51.19% |
| Open | 55.10 | Prev Close | 54.94 | Low | 53.50 | High | 55.44 | Mkt Cap | 8.19B |
| Vol | 1.99M | Avg Vol | 2.33M | EPS | 2.86 | P/E | 18.71 | Forward P/E | 18.63 |
| Beta | 1.68 | Short Ratio | 15.25 | Inst. Own | 70.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 42.89 | 200-d Avg | 34.54 | 1yr Est | 51.71 |
TGTX News
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat cli
3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, b
TG Therapeutics shares are trading higher on Wednesday as positive topline Phase 1 data fuels fresh
US stocks down, Dow Jones fell 150 pts on Wed. Caseys General Stores Inc (CASY) shares up 14.4% afte
TGTX stock rises on positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis. See what
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL obser
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL obser
Shares of TG Therapeutics Inc (NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial
Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen curre
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the publication of data from a post-hoc pooled